Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin for Benzodiazepine Dependence
NCT01893632Phase 2Terminated
- Sponsor
- New York State Psychiatric Institute
- Start
- Jul 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gabapentin in benzodiazepine dependence, sponsored by New York State Psychiatric Institute. Primary endpoint: Abstinence From Benzodiazepine Use at 12 weeks. Started Jul 2013; status: terminated.
02
Drugs
gabapentin
03
Conditions
benzodiazepine dependence
Beyond the preview
Go deeper on NCT01893632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01893632.